Effect of active A β immunotherapy on neurons in human Alzheimer's disease

Journal of Pathology

Volumn 235, Issue 5, 2015, Pages 721-730

  Paquet, Claire ^a,b   Amin, Jay ^c   Mouton Liger, François ^a,b   Nasser, Mariam ^c   Love, Seth ^d   Gray, Françoise ^a   Pickering, Ruth M ^c   Nicoll, James Ar ^c,e   Holmes, Clive ^c,f   Hugon, Jacques ^a,b   Boche, Delphine ^c  

^a AP HP University of Paris   (France)

^b INSERM   (France)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^f MOORGREEN HOSPITAL   (United Kingdom)

Author keywords

A immunotherapy; amyloid; neurodegeneration; neuron; PKR; tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; CD32 ANTIGEN; CD68 ANTIGEN; NEUROFILAMENT PROTEIN; NEURON SPECIFIC NUCLEAR PROTEIN; TAU PROTEIN; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); AN-1792; BIOLOGICAL MARKER; CELL NUCLEUS ANTIGEN; MAPT PROTEIN, HUMAN; NERVE PROTEIN; PEPTIDE FRAGMENT; PROTEIN KINASE R;

ADULT; AGED; ALZHEIMER DISEASE; ANTIBODY RESPONSE; ARTICLE; BRAIN SPONGIOSIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MICROGLIA; MIDDLE AGED; NEOCORTEX; NERVE CELL; NERVE DEGENERATION; NEURITE; ONSET AGE; PRIORITY JOURNAL; SURVIVAL TIME; VERY ELDERLY; AMYLOID PLAQUE; AUTOPSY; CASE CONTROL STUDY; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; NEUROFIBRILLARY TANGLE; PATHOLOGY; PHOSPHORYLATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANTIGENS, NUCLEAR; AUTOPSY; BIOMARKERS; CASE-CONTROL STUDIES; EIF-2 KINASE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOCORTEX; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEUROFIBRILLARY TANGLES; NEUROFILAMENT PROTEINS; NEURONS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PLAQUE, AMYLOID; TAU PROTEINS; TREATMENT OUTCOME;

EID: 84924614515     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4491     Document Type: Article

References (50)

1. Wimo A, Jonsson L, Bond J, et al., The worldwide economic impact of dementia 2010. Alzheimers Dement 2013; 9: 1-11 e13.
2. Knopman DS, Parisi JE, Salviati A, et al., Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003; 62: 1087-1095.
3. Jack CR Jr, Knopman DS, Jagust WJ, et al., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128.
4. Hardy J., The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009; 110: 1129-1134.
5. Schenk D, Barbour R, Dunn W, et al., Immunization with amyloid-β attenuates Alzheimer's-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177.
6. Morgan D, Diamond DM, Gottschall PE, et al., Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-985.
7. Bard F, Cannon C, Barbour R, et al., Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-919.
8. Buttini M, Masliah E, Barbour R, et al., β-Amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 2005; 25: 9096-9101.
9. Janus C, Pearson J, McLaurin J, et al., Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-982.
10. Dodart JC, Bales KR, Gannon KS, et al., Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci 2002; 5: 452-457.
11. Nicoll JA, Wilkinson D, Holmes C, et al., Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003; 9: 448-452.
12. Nicoll JA, Barton E, Boche D, et al., Aβ species removal after Aβ42 immunization. J Neuropathol Exp Neurol 2006; 65: 1040-1048.
13. Boche D, Donald J, Love S, et al., Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunization in Alzheimer's disease. Acta Neuropathol 2010; 120: 13-20.
14. Rinne JO, Brooks DJ, Rossor MN, et al., 11C-PiB PET assessment of change in fibrillar amyloid-βload in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9: 363-372.
15. Ostrowitzki S, Deptula D, Thurfjell L, et al., Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012; 69: 198-207.
16. Holmes C, Boche D, Wilkinson D, et al., Long-term effects of Aβ42 immunization in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-223.
17. Boche D, Zotova E, Weller RO, et al., Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain. Brain 2008; 131: 3299-3310.
18. Roher AE, Maarouf CL, Daugs ID, et al., Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient. J Alzheimers Dis 2011; 24: 315-325.
19. Orgogozo JM, Gilman S, Dartigues JF, et al., Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003; 61: 46-54.
20. Sperling R, Salloway S, Brooks DJ, et al., Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012; 11: 241-249.
21. Blennow K, Zetterberg H, Rinne JO, et al., Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012; 69: 1002-1010.
22. Serrano-Pozo A, William CM, Ferrer I, et al., Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology. Brain 2010; 133: 1312-1327.
23. Vellas B, Black R, Thal LJ, et al., Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009; 6: 144-151.
24. Salloway S, Sperling R, Fox NC, et al., Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 322-333.
25. Doody RS, Thomas RG, Farlow M, et al., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 311-321.
26. Aisen PS, Vellas B, Hampel H,. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov 2013; 12: 324.
27. Fox NC, Black RS, Gilman S, et al., Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005; 64: 1563-1572.
28. Garcia MA, Meurs EF, Esteban M,. The dsRNA protein kinase PKR: virus and cell control. Biochimie 2007; 89: 799-811.
29. Paquet C, Mouton-Liger F, Meurs EF, et al., The PKR activator PACT is induced by Aβ: involvement in Alzheimer's disease. Brain Pathol 2012; 22: 219-229.
30. Bose A, Mouton-Liger F, Paquet C, et al., Modulation of tau phosphorylation by the kinase PKR: implications in Alzheimer's disease. Brain Pathol 2011; 21: 189-200.
31. Zotova E, Bharambe V, Cheaveau M, et al., Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. Brain 2013; 136: 2677-2696.
32. Dubois B, Feldman HH, Jacova C, et al., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746.
33. Bayer AJ, Bullock R, Jones RW, et al., Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 2005; 64: 94-101.
34. Chang RC, Suen KC, Ma CH, et al., Involvement of double-stranded RNA-dependent protein kinase and phosphorylation of eukaryotic initiation factor-2α in neuronal degeneration. J Neurochem 2002; 83: 1215-1225.
35. Suen KC, Yu MS, So KF, et al., Upstream signaling pathways leading to the activation of double-stranded RNA-dependent serine/threonine protein kinase in β-amyloid peptide neurotoxicity. J Biol Chem 2003; 278: 49819-49827.
36. Mouton-Liger F, Paquet C, Dumurgier J, et al., Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease. Biol Psychiat 2012; 71: 829-835.
37. Dumurgier J, Mouton-Liger F, Lapalus P, et al., Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer's disease. PLoS One 2013; 8: e53587.
38. Zotova E, Holmes C, Johnston D, et al., Microglial alterations in human Alzheimer's disease following Aβ42 immunization. Neuropathol Appl Neurobiol 2011; 37: 513-524.
39. Masliah E, Honer WG, Mallory M, et al., Topographical distribution of synaptic-associated proteins in the neuritic plaques of Alzheimer's disease hippocampus. Acta Neuropathol 1994; 87: 135-142.
40. Spires TL, Hyman BT,. Neuronal structure is altered by amyloid plaques. Rev Neurosci 2004; 15: 267-278.
41. Lee JW, Lee YK, Yuk DY, et al., Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of β-amyloid generation. J Neuroinflamm 2008; 5: 37.
42. Soscia SJ, Kirby JE, Washicosky KJ, et al., The Alzheimer's disease-associated amyloid β-protein is an antimicrobial peptide. PLoS One 2010; 5: e9505.
43. Krstic D, Madhusudan A, Doehner J, et al., Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflamm 2012; 9: 151.
44. Patton RL, Kalback WM, Esh CL, et al., Amyloid-β peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 2006; 169: 1048-1063.
45. Maarouf CL, Daugs ID, Kokjohn TA, et al., The biochemical aftermath of anti-amyloid immunotherapy. Mol Neurodegener 2010; 5: 39.
46. Walsh DM, Klyubin I, Fadeeva JV, et al., Naturally secreted oligomers of amyloid β-protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-539.
47. Shankar GM, Li S, Mehta TH, et al., Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-842.
48. Li S, Hong S, Shepardson NE, et al., Soluble oligomers of amyloid β-protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009; 62: 788-801.
49. Alzforum: http://www.alzforum.org/new/detail.asp?id=3254 [accessed 24 August 2012]
50. Panza F, Solfrizzi V, Imbimbo BP, et al., Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol 2014; 10: 405-419.